Friday 04 Apr
Engineer Mohamed Shimi, Minister of Public Business Sector, and Dr. Ali Al-Ghamrawy, Head of the Egyptian Drug Authority, conducted an extensive field tour of a number of companies affiliated with the Holding Company for Pharmaceuticals, Chemicals, and Medical Supplies, namely: Arab Drug Company (ADCO), Memphis Pharmaceuticals, and Nile Pharmaceuticals.
The tour aimed to inspect the development work that has taken place in the production areas, units, and lines of these companies, within the framework of the Ministry's strategy to enhance production and competitiveness, comply with Good Manufacturing Practices (GMP) requirements, and support Egyptian drug security.
Minister Shimi emphasized the Ministry's interest in
developing the pharmaceutical industry in the subsidiary companies, enhancing
the role of the Holding Company in supporting Egyptian drug security, and
keeping pace with the latest international standards. He stressed the
importance of the development projects taking place in the subsidiary
companies, developing production lines, localizing modern technology,
preserving available assets and resources, and making good use of them to
enhance productivity and competitiveness.
He pointed out that the Ministry is working closely with the
Egyptian Drug Authority to enhance compliance with GMP requirements, modernize
production lines, and improve infrastructure, to enhance competitiveness and
support Egyptian exports. He focused on investing in human capital, training
workers in the sector and raising their efficiency.
The head of the authority emphasized the pivotal role of the
Holding Company's factories in the state's program to enhance Egyptian national
drug security. He praised the efforts made to improve drug quality and develop
production lines to keep pace with technological developments in the
pharmaceutical field. He affirmed the Egyptian Drug Authority's keenness to
provide a supportive environment for investment in the pharmaceutical sector,
by developing infrastructure and enhancing cooperation with national companies
to expand the scope of pharmaceutical production.
The Arab Drug Company (ADCO) development work included
production departments and areas with investments exceeding 600 million pounds.
The developments included production areas for solid pharmaceutical
preparations, inhalation aerosol production, the new water station, and raw
material and warehouse dispensing areas. The company achieved sales of 777
million pounds during the period from July 2024 to the end of February 2025,
with a growth rate of 39% compared to the same period last year, while profits
reached 103 million pounds.
Memphis Pharmaceuticals development took place in a number
of production areas to comply with GMP standards, most notably the new
ointments, creams, and lotions area, the tablet striping area, and ampoule
production areas. The company achieved profit growth of 223% and revenue growth
of 83% during the first half of the 2024-2025 fiscal year.
In Nile Pharmaceuticals, five production areas were developed to comply with GMP requirements, including ointments, creams, suppositories, replacement solutions, and effervescent powders. The development reflected on enhancing production efficiency and increasing capacity by 37% in effervescent powders, 50% in syrups and ointments, and 36% in replacement solutions.
